Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: May 2, 2000
Last updated: December 17, 2013
Last verified: March 2007

May 2, 2000
December 17, 2013
October 1997
Not Provided
All-cause mortality [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00005586 on Archive Site
  • Death from colorectal cancer [ Designated as safety issue: No ]
  • Disease recurrence [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed
A UKCCCR Study of Adjuvant Chemotherapy for Colorectal Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether chemotherapy is more effective than observation in patients who have had surgery to remove colorectal cancer.

PURPOSE: This randomized phase III trial is studying leucovorin and fluorouracil to see how well they work compared to observation in treating patients with colorectal cancer that has been surgically removed.


  • Compare all-cause mortality in patients with resected colorectal cancer treated with adjuvant chemotherapy with L-leucovorin and fluorouracil vs observation.
  • Compare the recurrence rates in patients treated with this regimen vs observation.
  • Compare the effectiveness of a monthly 5-day schedule vs a once weekly schedule of L-leucovorin and fluorouracil in this patient population.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to receive adjuvant chemotherapy (arm I) or undergo observation only (arm II).

  • Arm I: Within 12 weeks of surgery, patients receive L-leucovorin IV followed by fluorouracil IV on days 1-5 every 4 weeks for 6 courses. Alternatively, patients may receive L-leucovorin IV followed by fluorouracil IV on day 1 weekly for 30 weeks.
  • Arm II: Patients undergo observation. Patients are followed annually.

PROJECTED ACCRUAL: A total of 2,500 patients (1,250 per arm) will be accrued for this study.

Phase 3
Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Colorectal Cancer
  • Drug: L-leucovorin
  • Drug: fluorouracil
  • Procedure: adjuvant therapy
Not Provided
Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007 Dec 15;370(9604):2020-9.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided


  • Completely resected stage II or III colorectal cancer
  • No distant metastases
  • No positive resection margins
  • No positive peritoneal washings



  • 18 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • No clear definite indication for, or contraindication against, systemic chemotherapy with L-leucovorin and fluorouracil


Biologic therapy:

  • Not specified


  • No concurrent chemotherapy in observation only arm

Endocrine therapy:

  • Not specified


  • Concurrent radiotherapy allowed in adjuvant chemotherapy arm provided chemotherapy administered on the once weekly schedule


  • See Disease Characteristics
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
CDR0000067660, NCRI-QUASAR1, EU-99053, UKCCCR-QUASAR1, ISRCTN82375386
Not Provided
Not Provided
Not Provided
Not Provided
Institute of Cancer Research, United Kingdom
Not Provided
Study Chair: Norman Williams, MD Royal London Hospital
National Cancer Institute (NCI)
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP